Latest revenue
$40.2M
as of 2024-09-30
Latest net income
$-21.9M
as of 2024-09-30
Net margin
-54.5%
as of 2024-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think ATRA is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $90.2M
- Enterprise value
- $81.8M
- P/E (trailing)
- 2.8×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $19.14
- 52-wk low
- $3.92
- Beta
- —
- Shares out
- 9.0M
5-year trend
What this company does
Item 1. Business Overview Atara Biotherapeutics is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune disease. Tab-cel®(tabelecleucel), has received marketing authorization approval under the proprietary name Ebvallo™ by the European Commission (EC) for commercial sale and use in the European Economic Area (EEA), by the Medicines and Healthcare products Regulatory Agency (MHRA) for commercial sale and use in the United Kingdom (UK) and by Swissmedic for commercial sale and use in Switzerland. We partnered with Pierre Fabre Medicament (Pierre Fabre) for…
AI summary unavailable — showing raw filing excerpt
Generated from ATRA's filing dated 2026-03-16
Key risks
Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. Investors should carefully consider all of the risk factors and uncertainties described below, in addition to the other information contained in this Annual Report on Form 10-K, including the section of this report titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes, before investing in our common stock. The risks described below may not be the only ones relating to our company and additional risks that we currently believe are immaterial may also affect us. If any of these risks, including those described…
AI summary unavailable — showing raw filing excerpt
Generated from ATRA's filing dated 2026-03-16
Profitability
Operating margin
29.7%
145.9%Net margin
27.1%
140.9%Return on equity
-84.9%
198.6%Return on assets
161.5%
306.4%Leverage
Debt / equity
-1.53×
27.3%Debt / assets
290.3%
52.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-4.1M | -110.9% | — |
Q4 2025 2025-12-31 | — | — | $-3.4M | +73.2% | — |
Q3 2025 2025-09-30 | — | — | $-4.3M | +80.4% | — |
Q2 2025 2025-06-30 | — | — | $2.4M | +112.5% | — |
Q1 2025 2025-03-31 | — | — | $38.0M | +219.7% | — |
Q4 2024 2024-12-31 | $32.8M | — | $-12.7M | — | -38.8% |
Q3 2024 2024-09-30 | $40.2M | +1779.8% | $-21.9M | +68.6% | -54.5% |
Q2 2024 2024-06-30 | $28.6M | +2892.7% | $-19.0M | +73.2% | -66.5% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ATRA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$5.6M
Insider selling
$3.9M
Net activity
+$1.7M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ATRA
Institutional value
$3.7M
Total shares held
912.9K
Distinct holders
17
-24 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | MACKENZIE FINANCIAL CORP | 313.6K | $1.5M | +255.0K (+434.6%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 217.9K | $1.0M | — | New |
| 3 | BlackRock, Inc. | 79.0K | $373.8K | +11.9K (+17.8%) | Added |
| 4 | UBS Group AG | 50.1K | $236.8K | +48.7K (+3484.1%) | Added |
| 5 | STALEY CAPITAL ADVISERS INC | 50.0K | $236.5K | +0 (+0.0%) | No change |
| 6 | JANE STREET GROUP, LLC | 33.9K | $160.2K | +19.9K (+142.1%) | Added |
| 7 | VANGUARD FIDUCIARY TRUST CO | 33.6K | $159.0K | — | New |
| 8 | SBI Securities Co., Ltd. | 1.6K | $7.4K | +170 (+12.1%) | Added |
| 9 | Vanguard Global Advisers, LLC | 1.5K | $6.9K | — | New |
| 10 | WELLS FARGO & COMPANY/MN | 251 | $1.2K | +0 (+0.0%) | No change |
| 11 | JPMORGAN CHASE & CO | 216 | $933 | +0 (+0.0%) | No change |
| 12 | Banque Transatlantique SA | 176 | $906 | -176 (-50.0%) | Trimmed |
| 13 | RHUMBLINE ADVISERS | 175 | $827 | +0 (+0.0%) | No change |
| 14 | ACADIAN ASSET MANAGEMENT LLC | 130.9K | $617 | +76.9K (+142.2%) | Added |
| 15 | BNP PARIBAS FINANCIAL MARKETS | 58 | $274 | +12 (+26.1%) | Added |
| 16 | KERR FINANCIAL PLANNING Corp | 24 | $116 | +0 (+0.0%) | No change |
| 17 | CITIGROUP INC | 1 | $5 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ATRA's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.